Decibel Therapeutics
Biotechnology ResearchView the employees at
Decibel Therapeutics-
Pete Weber CMO at Decibel Therapeutics
-
Greater Boston
-
Rising Star
C. Tyler Mitchell, CPA Manager, Financial Reporting at Decibel Therapeutics-
Greater Boston
-
Rising Star
Adrian Timmers PHARMACEUTICAL RESEARCH LEADER | VP | AAV GENE THERAPY | CRISPR | LNP-
Burlington, Massachusetts, United States
-
Rising Star
Ricky Santiago IT Administrator at Decibel Therapeutics-
Boston, Massachusetts, United States
-
Rising Star
Yoojin Chung Scientist at Decibel Therapeutics-
Boston, Massachusetts, United States
-
Rising Star
Overview
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders. Guidelines: https://bit.ly/3IzmNvU
-